LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Pfizer

Suletud

SektorTervishoid

23.35 1.04

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

23.09

Max

23.57

Põhinäitajad

By Trading Economics

Sissetulek

2.6B

3B

Müük

-4B

14B

P/E

Sektori keskmine

17

51.198

Aktsiakasum

0.92

Dividenditootlus

7.33

Kasumimarginaal

21.633

Töötajad

81,000

EBITDA

2.5B

5.1B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+18.59% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

7.33%

2.40%

Järgmine tulemuste avaldamine

29. juuli 2025

Järgmine dividendimakse kuupäev

13. juuni 2025

Turustatistika

By TradingEconomics

Turukapital

-12B

133B

Eelmine avamishind

22.31

Eelmine sulgemishind

23.35

Uudiste sentiment

By Acuity

40%

60%

129 / 380 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Pfizer Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. mai 2025, 04:13 UTC

Suurimad hinnamuutused turgudel

Biotech Company 3SBio's Shares Surge After $6 Billion Licensing Deal With Pfizer

1. mai 2025, 18:41 UTC

Suurimad hinnamuutused turgudel

Arvinas Shares Drop; Cancels Two Drug Trials With Pfizer Amid Capital Markets Challenges

29. apr 2025, 11:24 UTC

Tulu

Pfizer 1Q Revenue Slides as Paxlovid Sales Fade

27. mai 2025, 17:59 UTC

Peamised uudised

Kennedy, Skipping Regulatory Steps, Limits Use of Covid-19 Shots -- Barrons.com

20. mai 2025, 14:46 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid. -- Barrons.com

15. mai 2025, 15:20 UTC

Peamised uudised

New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel -- WSJ

12. mai 2025, 22:14 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12. mai 2025, 18:45 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12. mai 2025, 17:14 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

12. mai 2025, 09:02 UTC

Kuumad aktsiad

Stocks to Watch: Amazon, Tesla, Apple, Maersk -- WSJ

7. mai 2025, 17:01 UTC

Peamised uudised

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7. mai 2025, 09:30 UTC

Peamised uudised

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

5. mai 2025, 15:13 UTC

Market Talk
Tulu

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

1. mai 2025, 14:07 UTC

Tulu

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1. mai 2025, 11:58 UTC

Tulu

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1. mai 2025, 11:06 UTC

Tulu

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1. mai 2025, 10:48 UTC

Tulu

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

29. apr 2025, 19:47 UTC

Tulu

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

29. apr 2025, 18:11 UTC

Tulu

Pfizer Stock's 7% Yield Makes It Look Like a Junk Bond -- But Better -- Barrons.com

29. apr 2025, 15:22 UTC

Tulu

Pfizer Earnings Beat Isn't Enough to Ease Stock Worries -- Barrons.com

29. apr 2025, 12:03 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Files 8K - Costs of Exits Or Disposals >PFE

29. apr 2025, 11:46 UTC

Tulu

Pfizer Stock Gains After Earnings Beat. Tariffs Aren't the Only Worry for Wall Street. -- Barrons.com

29. apr 2025, 11:42 UTC

Tulu

Pfizer Stock Falls After Earnings Beat. Tariffs Aren't the Only Worry. -- Barrons.com

29. apr 2025, 11:12 UTC

Tulu

Pfizer Earnings Beat. Tariffs Uncertainty Hinders Guidance. -- Barrons.com

29. apr 2025, 10:52 UTC

Tulu

Pfizer: Currently Trending Towards Upper End of 2025 Adj EPS Guidance Range

29. apr 2025, 10:51 UTC

Tulu

Pfizer: Believe We Can Be Agile in Navigating Uncertain and Volatile External Environment

29. apr 2025, 10:50 UTC

Tulu

Pfizer: On Track For Total Net Cost Savings $5.7B Through 2027

29. apr 2025, 10:47 UTC

Tulu

Pfizer: Expects to Continue to De-Lever in Prudent Manner

29. apr 2025, 10:47 UTC

Tulu

Pfizer: Current Fincl Guidance Does Not Anticipate Any Share Repurchases in 2025

29. apr 2025, 10:46 UTC

Tulu

Pfizer: "Unable to Predict" Tariff Impact "At This Time"

Võrdlus sarnastega

Hinnamuutus

Pfizer Prognoos

Hinnasiht

By TipRanks

18.59% tõus

12 kuu keskmine prognoos

Keskmine 27.69 USD  18.59%

Kõrge 33 USD

Madal 23 USD

Põhineb 18 Wall Streeti analüütiku instrumendi Pfizer 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

18 ratings

5

Osta

13

Hoia

0

Müü

Tehniline skoor

By Trading Central

22.855 / 23.85Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

129 / 380 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.